Get the Stockscreener App
54.25
5.59%
2.56
Spruce Biosciences Inc stock is traded at $54.25, with a volume of 103.49K.
It is up +5.59% in the last 24 hours and down -6.54% over the past month.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.
See More
Previous Close:
$51.69
Open:
$56.75
24h Volume:
103.49K
Relative Volume:
1.88
Market Cap:
$74.90M
Revenue:
$697.00K
Net Income/Loss:
$-38.97M
P/E Ratio:
-1.8659
EPS:
-29.075
Net Cash Flow:
$-33.33M
1W Performance:
-21.26%
1M Performance:
-6.54%
6M Performance:
-61.16%
1Y Performance:
-90.34%
1-Day Range:
$54.01
$56.75
1-Week Range:
$51.36
$74.00
52-Week Range:
$7.26
$543.38
Spruce Biosciences Inc Stock (SPRB) Company Profile
Name
Spruce Biosciences Inc
Sector
Industry
Phone
(415) 655-4168
Address
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
Compare SPRB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRB
Spruce Biosciences Inc
|
54.58 | 70.93M | 697.00K | -38.97M | -33.33M | -29.07 |
VRTX
Vertex Pharmaceuticals Inc
|
436.81 | 111.05B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
748.68 | 79.01B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
794.59 | 50.08B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
311.23 | 41.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.06 | 34.67B | 5.36B | 287.73M | 924.18M | 2.5229 |
Spruce Biosciences Inc Stock (SPRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-23-25 | Initiated | Oppenheimer | Outperform |
| Dec-03-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-28-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Dec-11-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-11-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-14-24 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-14-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-14-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Mar-14-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-14-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-21-24 | Initiated | Guggenheim | Buy |
| Dec-17-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | The Benchmark Company | Speculative Buy |
| Nov-16-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-19-21 | Initiated | H.C. Wainwright | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Nov-03-20 | Initiated | Cowen | Outperform |
| Nov-03-20 | Initiated | Credit Suisse | Outperform |
| Nov-03-20 | Initiated | RBC Capital Mkts | Outperform |
| Nov-03-20 | Initiated | SVB Leerink | Outperform |
View All
Spruce Biosciences Inc Stock (SPRB) Latest News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
SPRB Spruce Biosciences Inc. gains 3.53 percent even as Q4 2025 earnings miss analyst consensus estimates.Recovery Report - Xã Thanh Hà
Spruce Biosciences Prices Equity Offering to Raise Capital - TipRanks
Spruce Biosciences Enters Underwriting For $69 Million Equity Offering; Option Fully Exercised - TradingView
Spruce Biosciences prices $60M public offering at $50.00 per share - MSN
Spruce Biosciences (NASDAQ: SPRB) raises about $69.0 million in equity sale - Stock Titan
Spruce Biosciences (NASDAQ: SPRB) sells 1.15M shares, issues pre-funded warrants - Stock Titan
Why is Spruce Biosciences stock sinking Tuesday? - MSN
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Spruce Biosciences (SPRB) and AXT (AXTI) Stocks Decline Followin - GuruFocus
SPRB: New Offering Managed by Leading Investment Firms - GuruFocus
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Why Is Spruce Biosciences Stock Sinking Tuesday? - Benzinga
Morning Market Movers: LOCL, CLIK, SPRC, SPRB See Big Swings - RTTNews
Spruce Biosciences prices $60M public offering at $50 per share By Investing.com - Investing.com South Africa
Stock Market Today: Dow Jones, S&P 500 Futures Edge Higher With Eyes On Iran Talks—Apple, UnitedHealth, 3M In Focus - Benzinga
Why Amazon Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga
Spruce Biosciences locks in $60M raise at $50 a share - Stock Titan
Spruce Biosciences Prices Public Offering of Common Stock, Prefunded Warrants>SPRB - Moomoo
Spruce Biosciences (SPRB) Announces $60 Million Public Offering - GuruFocus
Spruce Biosciences Offering Expected to Close April 22 >SPRB - Moomoo
Spruce Biosciences launches public stock offering By Investing.com - Investing.com India
Spruce Biosciences Expects Gross Proceeds of $60M >SPRB - Moomoo
Spruce Biosciences prices $60M public offering at $50 per share - Investing.com Canada
Spruce Biosciences Announces Pricing Of Public Offering Of Common Stock And Pre-Funded Warrants - TradingView
Spruce Biosciences Begins Public Offering of Stock, Prefunded Warrants; Shares Fall After Hours - Moomoo
Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - The National Law Review
Spruce Biosciences announces proposed public offering of common stock, pre-funded warrants - MSN
Spruce Biosciences (SPRB) Sees 13% Drop Following Equity Offerin - GuruFocus
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Spruce Biosciences launches public stock offering - Investing.com
Spruce Biosciences Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants - TradingView
Spruce Biosciences (SPRB) seeks capital with common stock and pre-funded warrants offering - Stock Titan
SPRB Technical Analysis | Trend, Signals & Chart Patterns | SPRUCE BIOSCIENCES INC (NASDAQ:SPRB) - ChartMill
Top Anthem (ANTX) Competitors 2026 - MarketBeat
SPRB Stock Price, Quote & Chart | SPRUCE BIOSCIENCES INC (NASDAQ:SPRB) - ChartMill
Spruce Biosciences (NASDAQ: SPRB) sets 2026 virtual meeting and pay votes - Stock Titan
SPRB SEC FilingsSpruce Biosciences, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Spruce Biosciences, Inc. (SPRB) stock price, news, quote and history - Yahoo Finance UK
Wall Street experts predict that Spruce Biosciences (SPRB) may surge by 181.21%: Strategies for Trading - Bitget
Wall Street Analysts Believe Spruce Biosciences (SPRB) Could Rally 181.21%: Here's is How to Trade - Yahoo Finance
SPRB Earnings History & Surprises | EPS & Revenue Results | SPRUCE BIOSCIENCES INC (NASDAQ:SPRB) - ChartMill
SPRB Forecast, Price Target & Analyst Ratings | SPRUCE BIOSCIENCES INC (NASDAQ:SPRB) - ChartMill
Leerink Partners Maintains Spruce Biosciences (SPRB) Market Perform Recommendation - MSN
Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Spruce Stock Ignites: A 24% Surge Defies Gravity as Energy Winds Shift - Bitget
Citizens reiterates Spruce Biosciences stock rating on approval outlook - Investing.com
Citizens reiterates Spruce Biosciences stock rating on approval outlook By Investing.com - Investing.com India
Spruce Biosciences Inc Stock (SPRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Spruce Biosciences Inc Stock (SPRB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Gharib Samir M. | PRESIDENT AND CFO |
Dec 15 '25 |
Option Exercise |
0.00 |
1,009 |
0 |
8,447 |
| Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER |
Dec 15 '25 |
Option Exercise |
0.00 |
2,676 |
0 |
14,922 |
| Gharib Samir M. | PRESIDENT AND CFO |
Dec 11 '25 |
Option Exercise |
0.00 |
1,900 |
0 |
8,296 |
| Gharib Samir M. | PRESIDENT AND CFO |
Dec 10 '25 |
Option Exercise |
0.00 |
514 |
0 |
6,580 |
| Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER |
Dec 11 '25 |
Option Exercise |
0.00 |
4,950 |
0 |
15,192 |
| Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER |
Dec 10 '25 |
Option Exercise |
0.00 |
1,196 |
0 |
10,670 |
| Gharib Samir M. | PRESIDENT AND CFO |
Oct 20 '25 |
Option Exercise |
0.00 |
2,053 |
0 |
6,727 |
| Szwarcberg Javier B. | CHIEF EXECUTIVE OFFICER |
Oct 20 '25 |
Option Exercise |
0.00 |
4,784 |
0 |
11,013 |
| Parkman Healthcare Partners LL | 10% Owner |
Oct 06 '25 |
Buy |
17.91 |
256 |
4,585 |
1,307 |
| Parkman Healthcare Partners LL | 10% Owner |
Oct 06 '25 |
Sale |
19.14 |
257 |
4,920 |
1,050 |
1.40%
0.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):